» Articles » PMID: 16291810

Transformation of Breast Cells by Truncated Neurokinin-1 Receptor is Secondary to Activation by Preprotachykinin-A Peptides

Overview
Specialty Science
Date 2005 Nov 18
PMID 16291810
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer remains the cancer with the highest mortality among women in the United States. Peptides derived from the oncogenic Tac1 gene (full transcript: betaPPT-A) stimulate the proliferation of breast cancer cells (BCCs) via seven-transmembrane G protein-coupled neurokinin 1 (NK1) and NK2 receptors. The NK1 gene could generate full-length (NK1-FL) and truncated (NK1-Tr) transcripts. NK1-Tr lacks 100 residues in their cytoplasmic end, could couple to G proteins, and shows reduced efficiency with respect to internalization and desensitization. This study reports on a role of NK1-Tr in the transformation of nontumorigenic breast cells, and investigates whether Tac1 expression is linked to the generation of NK1-Tr. Western blots and Northern analyses showed coexpressions of NK1-Tr and NK1-FL in BCCs (cell lines and primary cells from patients with different stages of breast cancer). Stable transfections of betaPPT-A or NK1-Tr expression vectors in nontumorigenic cells showed each induces the expression of the other, consequently resulting in a transformed phenotype. Analyses with microarrays indicate similar patterns of cytokine production by NK1-Tr transfectants and BCCs, but not NK1-FL transfectants. These observations indicate tumor-promoting properties by NK1-Tr, but not NK1-FL. Overall, the oncogenic property of Tac1 in breast cells involves concomitant expression of NK1-Tr and vice versa, consequently leading to the production of cytokines with growth promoting functions.

Citing Articles

The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.

Martin-Garcia D, Tellez T, Redondo M, Garcia-Aranda M Curr Med Chem. 2023; 31(39):6487-6509.

PMID: 37861026 DOI: 10.2174/0109298673261625230924114406.


Association of Neurokinin-1 Receptor Signaling Pathways with Cancer.

Rodriguez F, Covenas R Curr Med Chem. 2023; 31(39):6460-6486.

PMID: 37594106 DOI: 10.2174/0929867331666230818110812.


Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor.

Zheng Y, Sang M, Liu F, Gu L, Li J, Wu Y Oncol Rep. 2023; 50(1).

PMID: 37203393 PMC: 10236268. DOI: 10.3892/or.2023.8568.


The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.

Munoz M, Arguelles S, Rosso M, Medina R, Covenas R, Ayala A Biomed Res Int. 2022; 2022:6291504.

PMID: 35434136 PMC: 9006081. DOI: 10.1155/2022/6291504.


Detection of neurokinin-1 receptor by immunohistochemistry in canine mammary gland tumours.

Song D, Oh Y, Kim J, Cheon D, Kim D, Seo K Vet Med Sci. 2020; 6(4):958-964.

PMID: 32657032 PMC: 7738737. DOI: 10.1002/vms3.323.


References
1.
Grotzer M, Janss A, Fung K, Biegel J, Sutton L, RORKE L . TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000; 18(5):1027-35. DOI: 10.1200/JCO.2000.18.5.1027. View

2.
Fong T, Anderson S, Yu H, Huang R, Strader C . Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol. 1992; 41(1):24-30. View

3.
Palma C, Maggi C . The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci. 2000; 67(9):985-1001. DOI: 10.1016/s0024-3205(00)00692-5. View

4.
Fan T, Hu D, Guard S, GRESHAM G, Watling K . Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol. 1993; 110(1):43-9. PMC: 2176009. DOI: 10.1111/j.1476-5381.1993.tb13769.x. View

5.
Hennig I, Laissue J, Horisberger U, Reubi J . Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer. 1995; 61(6):786-92. DOI: 10.1002/ijc.2910610608. View